Scholarlink

<p>The landscape of clinical microbiome research has dramatically evolved over the past decade. By leveraging in vivo and in vitro experimentation, multiomic approaches and computational biology, we have uncovered mechanisms of action and microbial metrics of association and identified effective ways to modify the microbiome in many diseases and treatment modalities. This Review explores recent advances in the clinical application of microbiome research over the past 5 years, while acknowledging existing barriers and highlighting opportunities. We focus on the translation of microbiome research into clinical practice, spearheaded by Food and Drug Administration (FDA)-approved microbiome therapies for recurrent <i>Clostridioides difficile</i> infections and the emerging fields of microbiome-based diagnostics and therapeutics. We highlight key examples of studies demonstrating how microbiome mechanisms, metrics and modifiers can advance clinical practice. We also discuss forward-looking perspectives on key challenges and opportunities toward integrating microbiome data into routine clinical practice, precision medicine and personalized healthcare and nutrition.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical translation of microbiome research

  • 期刊论文

  • 发表日期：

    2025年4月11日

查看全文
  • Jack A. Gilbert,
  • Meghan B. Azad,
  • Fredrik Bäckhed,
  • Martin J. Blaser,
  • Mariana Byndloss,
  • Charles Y. Chiu,
  • Hiutung Chu,
  • Lara R. Dugas,
  • Eran Elinav,
  • Sean M. Gibbons,
  • Katharine E. Gilbert,
  • Matthew R. Henn,
  • Suzanne L. Ishaq,
  • Ruth E. Ley,
  • Susan V. Lynch,
  • Eran Segal,
  • Tim D. Spector,
  • Philip Strandwitz,
  • Jotham Suez,
  • Carolina Tropini,
  • Katrine Whiteson,
  • Rob Knight

摘要

The landscape of clinical microbiome research has dramatically evolved over the past decade. By leveraging in vivo and in vitro experimentation, multiomic approaches and computational biology, we have uncovered mechanisms of action and microbial metrics of association and identified effective ways to modify the microbiome in many diseases and treatment modalities. This Review explores recent advances in the clinical application of microbiome research over the past 5 years, while acknowledging existing barriers and highlighting opportunities. We focus on the translation of microbiome research into clinical practice, spearheaded by Food and Drug Administration (FDA)-approved microbiome therapies for recurrent Clostridioides difficile infections and the emerging fields of microbiome-based diagnostics and therapeutics. We highlight key examples of studies demonstrating how microbiome mechanisms, metrics and modifiers can advance clinical practice. We also discuss forward-looking perspectives on key challenges and opportunities toward integrating microbiome data into routine clinical practice, precision medicine and personalized healthcare and nutrition.